Healthcare providers are encouraged to notify the registry staff of ongoing pregnancies where exposure to a registry medication has already occurred. NC 28405 Information collected at the time of registration includes timing, dose, and duration of the drug exposure, estimated date of delivery, and sufficient contact information to allow for follow-up of the subsequent pregnancy outcome.
Measures are in place to protect patient confidentiality.
Around the patient's estimated date of delivery a short follow-up form is sent to the registering healthcare provider to report on the pregnancy course and outcome. An interim report for each registry is prepared semiannually following an independent review of data by a scientific advisory committee with expertise in obstetrics, teratology, epidemiology, pediatrics, internal medicine, clinical genetics, and the relevant therapeutic areas. This report is made available to interested healthcare providers upon request by calling the registry. If you are unable to or do not wish to download Acrobat Reader, but still wish to receive complete Prescribing Information, please click here . This site is intended for US residents only.